Roche’s new targeted lung cancer treatment Alecensa has shown itself to be superior to Pfizer’s established rival Xalkori in a head-to-head trial as a first line treatment.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
